Ilyang Pharmaceutical Co Ltd (KO:007575) — Stock Price

₩7780.00 KRW
▲ 3.87% today

Ilyang Pharmaceutical Co Ltd (KO:007575) is currently trading at ₩7780.00 KRW, up 3.87% today. Over the past 52 weeks, shares have ranged between ₩7000.00 and ₩13640.00. This page tracks Ilyang Pharmaceutical Co Ltd's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Ilyang Pharmaceutical Co Ltd stock valuation.

Ilyang Pharmaceutical Co Ltd (007575) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Ilyang Pharmaceutical Co Ltd's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.

Ilyang Pharmaceutical Co Ltd Income Statement — Revenue, Profit & Earnings by Year

Ilyang Pharmaceutical Co Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue ₩268.86 Billion ₩266.67 Billion ₩383.81 Billion ₩371.35 Billion ₩343.33 Billion
Cost of Revenue ₩157.39 Billion ₩150.18 Billion ₩167.78 Billion ₩166.94 Billion ₩161.62 Billion
Gross Profit ₩111.48 Billion ₩116.49 Billion ₩216.03 Billion ₩204.40 Billion ₩181.71 Billion
Research & Development ₩24.74 Billion ₩23.75 Billion ₩25.96 Billion ₩20.20 Billion ₩19.72 Billion
SG&A ₩23.94 Billion ₩23.95 Billion ₩96.56 Billion ₩89.80 Billion ₩82.46 Billion
Total Operating Expenses ₩257.86 Billion ₩250.29 Billion ₩343.40 Billion ₩330.32 Billion ₩309.23 Billion
Operating Income ₩11.00 Billion ₩16.38 Billion ₩40.41 Billion ₩41.03 Billion ₩34.10 Billion
EBITDA — — ₩56.85 Billion ₩53.64 Billion ₩44.07 Billion
EBIT — — ₩40.41 Billion ₩41.03 Billion ₩34.10 Billion
Interest Expense ₩2.93 Billion ₩3.23 Billion ₩2.46 Billion ₩2.06 Billion ₩3.02 Billion
Income Before Tax ₩12.28 Billion ₩-1.80 Billion ₩41.33 Billion ₩38.93 Billion ₩28.39 Billion
Income Tax Expense — — ₩9.59 Billion ₩12.97 Billion ₩6.85 Billion
Net Income ₩10.26 Billion ₩-2.41 Billion ₩19.24 Billion ₩14.38 Billion ₩10.88 Billion

Ilyang Pharmaceutical Co Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Ilyang Pharmaceutical Co Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets ₩431.21 Billion ₩356.66 Billion ₩498.19 Billion ₩494.27 Billion ₩439.12 Billion
Total Current Assets ₩125.37 Billion ₩114.20 Billion ₩200.73 Billion ₩203.56 Billion ₩162.50 Billion
Cash & Equivalents — — — — —
Short-term Investments ₩8.49 Billion ₩6.78 Billion ₩5.42 Billion ₩34.34 Billion ₩270.87 Million
Net Receivables ₩44.96 Billion ₩46.47 Billion ₩60.15 Billion ₩63.16 Billion ₩58.68 Billion
Inventory ₩59.87 Billion ₩51.78 Billion ₩61.37 Billion ₩41.19 Billion ₩48.59 Billion
Property, Plant & Equipment — — ₩199.12 Billion ₩198.31 Billion ₩185.97 Billion
Goodwill — — — — —
Total Liabilities ₩189.63 Billion ₩160.25 Billion ₩206.33 Billion ₩222.51 Billion ₩194.19 Billion
Total Current Liabilities ₩156.90 Billion ₩139.19 Billion ₩186.86 Billion ₩198.21 Billion ₩177.15 Billion
Long-term Debt ₩14.70 Billion ₩6.00 Billion — ₩5.02 Billion —
Net Debt ₩102.91 Billion ₩71.71 Billion ₩25.02 Billion ₩53.35 Billion ₩61.40 Billion
Total Stockholder Equity ₩237.99 Billion ₩196.41 Billion ₩234.65 Billion ₩224.11 Billion ₩207.19 Billion
Retained Earnings ₩61.10 Billion ₩25.55 Billion ₩58.99 Billion ₩43.55 Billion ₩31.41 Billion

Ilyang Pharmaceutical Co Ltd Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Ilyang Pharmaceutical Co Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow ₩5.61 Billion ₩14.62 Billion ₩29.94 Billion ₩67.02 Billion ₩57.48 Billion
Capital Expenditures ₩40.62 Billion ₩6.83 Billion ₩4.08 Billion ₩12.91 Billion ₩10.17 Billion
Free Cash Flow ₩-35.01 Billion ₩7.79 Billion ₩9.40 Billion ₩45.67 Billion ₩32.86 Billion
Investing Cash Flow — — ₩7.59 Billion ₩-21.34 Billion ₩-21.16 Billion
Financing Cash Flow — — ₩-23.40 Billion ₩-43.13 Billion ₩-30.96 Billion
Dividends Paid ₩2.97 Billion ₩2.99 Billion ₩3.94 Billion ₩8.77 Billion ₩4.90 Billion
Stock-Based Compensation — — — — —
Depreciation ₩9.82 Billion ₩11.97 Billion ₩13.06 Billion ₩12.65 Billion ₩12.66 Billion
Change in Cash ₩881.17 Million ₩-3.76 Billion ₩11.87 Billion ₩6.39 Billion ₩5.45 Billion

Ilyang Pharmaceutical Co Ltd Earnings History — EPS Actual vs. Analyst Estimates

Track Ilyang Pharmaceutical Co Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 13, 2026 — — —
Jan 30, 2026 — — —
Nov 12, 2025 — — —
Aug 12, 2025 31.38 — —
May 15, 2025 — — —
Jan 31, 2025 — — —
Nov 12, 2024 — — —